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Abstract. Endoscopic submucosal dissection (ESD) enables 
the curative resection of early gastric cancer (EGC); however, 
little information is available on the long-term outcomes of 
ESD. This study was conducted to clarify the clinical outcomes 
of a large number of patients with EGC who underwent ESD. 
The early outcomes were assessed in 1,209 patients and the 
long-term outcomes were assessed in 300 patients at a follow-up 
>5 years after the ESD procedure. The overall survival rates 
were compared between indication and expanded-indication 
groups, and between the patients who did or did not undergo 
additional surgery in an out-of-indication group. Overall 
survival rates were also compared among different age 
groups. In total, 617 lesions were classed as the indication 
group, 507 as the expanded-indication group and 208 as the 
out-of-indication group. Curative resection rates were 96.6% 
and 91.5% in the indication and expanded-indication groups, 
respectively. In terms of the long-term outcomes, 20 of the 
146 patients in the indication group, 15 of the 105 patients in 
the expanded-indication group and one of the 23 patients who 
underwent additional surgery in the out-of-indication group 
succumbed due to causes other than gastric cancer. Among 
the 26 patients who did not undergo additional surgery in the 
out-of-indication group, 10 mortalities occurred, including 
one due to gastric cancer. The five‑year survival rates were 
not significantly different between the indication and 
expanded-indication groups. In the out-of-indication group, 
the five‑year survival rate for the patients who did not undergo 
additional surgery (65.0%) was significantly lower than that 
for those who did undergo additional surgery (100%) (P<0.01). 
The five‑year survival rate of patients aged >80 years (67.1%) 
was significantly lower than that of the younger patients 
(<60 years, 91.6%; sixties, 93.0%; seventies, 84.5%) (P<0.0001). 
In conclusion, although expanded-indication of ESD for EGC 
is appropriate, comorbidities require consideration in elderly 
patients.
Introduction
Early gastric cancer (EGC) is defined as gastric cancer that is 
confined to the mucosa or submucosa (T1 cancer), irrespec-
tive of the presence of regional lymph node metastases (1). 
In 1995, it was reported that almost 10,000 cases of EGC 
are detected annually in Japan, accounting for 40-50% of all 
gastric cancers (2).
Endoscopic submucosal dissection (ESD) is widely recog-
nized as a safe and effective treatment for EGC (3-6). However, 
little information is available concerning the long-term 
outcomes of ESD in large numbers of patients. 
The gold standard study design for evaluation of the efficacy 
of endoscopic treatment of EGC is a long-term, large-scale, 
randomized controlled trial. The excellent prognosis following 
surgical treatment of EGC, particularly in cases indicated for 
endoscopic resection, makes randomized controlled trials 
unethical. Therefore, the feasible evidence of the efficacy of 
EMR/ESD comes from long-term clinical follow-up data.
In the present study, the clinical outcomes of a large number 
of patients with EGC who underwent ESD were investigated.
Patients and methods
Patients. A total of 1,332 EGCs in 1,209 consecutive patients 
were treated by ESD at the affiliated hospitals of Nagasaki 
University Hospital from January 2001 to December 2010. 
The indications for ESD were determined by the presence or 
absence of nodal metastasis (7-9) and according to the criteria 
for endoscopic resection proposed in the Treatment Guidelines 
for Gastric Cancer in Japan (10). The indication criteria were 
defined as differentiated‑type mucosal cancer without ulcer-
ation, ≤20 mm in diameter. The expanded‑indication criteria 
were defined as follows: Differentiated‑type mucosal cancer 
without ulceration, irrespective of tumor size; differenti-
Early and long‑term outcomes of endoscopic submucosal 
dissection for early gastric cancer in a large patient series
KEN OHNITA1,  HAJIME ISOMOTO1,  SABURO SHIKUWA2,  HIROYUKI YAJIMA1,  HITOMI MINAMI1,   
KAYOKO MATSUSHIMA1,  YUKO AKAZAWA1,  NAOYUKI YAMAGUCHI1,  EIICHIRO FUKUDA1,   
HITOSHI NISHIYAMA1,  FUMINAO TAKESHIMA1  and  KAZUHIKO NAKAO1
1Department of Gastroenterology and Hepatology, Nagasaki University Hospital, Nagasaki-shi, Nagasaki 852-8501;  
2Sankokai Miyazaki Hospital, Isahaya-shi, Nagasaki 854-0066, Japan
Received September 6, 2013;  Accepted December 31, 2013
DOI: 10.3892/etm.2014.1488
Correspondence to: Dr Hajime Isomoto or Dr Ken Ohnita, 




Key words: endoscopic submucosal dissection, early gastric cancer, 
early outcomes, long-term outcomes
OHNITA et al:  ENDOSCOPIC SUBMUCOSAL DISSECTION OUTCOMES FOR GASTRIC CANCER 595
ated‑type mucosal cancer with ulceration, ≤30 mm in diameter; 
differentiated-type minute (<500 µm from the muscularis 
mucosae) submucosal invasive cancer, ≤30 mm in diameter; 
and undifferentiated-type mucosal cancer without ulceration, 
≤20 mm in diameter with no lymphovascular involvement. The 
out‑of‑indication criteria were defined as EGCs that did not 
meet the indication criteria or the expanded-indication criteria. 
Written informed consent was obtained from each patient.
ESD. The EGCs were first identified and demarcated using 
white-light endoscopy and chromoendoscopy with indigo 
carmine solution, after which marking around the lesions 
was performed by cautery with a needle knife. Glycerol 
(10% glycerol and 5% fructose; Chugai Pharmaceutical Co. 
Ltd., Tokyo, Japan) or MucoUp® (Johnson and Johnson Co. 
Ltd., Tokyo, Japan) were then injected into the submucosal 
layer to lift the mucosa. A circumferential mucosal incision 
was made around the lesion using an insulation-tipped (IT) 
Knife 2 (Olympus Medical Systems Corp., Tokyo, Japan) or 
a Flush Knife (Fujifilm Corp., Tokyo, Japan). Submucosal 
dissection was performed using the IT Knife 2, a Hook 
Knife (Olympus Medical Systems Corp.) or the Flush Knife 
to achieve complete removal of the lesion. High-frequency 
generators (ICC 200 or VIO 300D; ERBE Elektromedizin 
GmbH, Tübingen, Germany) were used during marking, 
incision of the gastric mucosa and exfoliation of the gastric 
submucosa.
Early outcomes. Early outcomes (perforation, bleeding rate 
and curability) were assessed for the 1,332 EGCs in the 
1,209 consecutive patients. The patients included 882 men and 
327 women, with a mean age of 72 years (range, 33-95 years). 
Perforation was diagnosed endoscopically or by the presence 
of free air on an abdominal plain radiograph or computed 
tomography scan. Procedure‑associated bleeding was defined 
as bleeding that required transfusion or surgical intervention, 
or bleeding that caused the hemoglobin level to decrease by 
2 g/dl (11).
En bloc resection refers to a resection in one piece (11). 
The curability of ESD was classified as either curative or 
non-curative (11,12). Resections were deemed curative when 
a tumor was excised en bloc and was within the indication 
or expanded-indication criteria with tumor-free lateral and 
vertical margins and no lymphovascular invasion. When histo-
logical evaluation was challenging or identified that a lesion 
was outside the indication or expanded-indication criteria 
and/or that it had a positive margin or lymphovascular inva-
sion, the curability was defined as non‑curative.
Long‑term outcomes. Long-term outcomes were assessed 
for a total of 342 EGCs in 319 consecutive patients treated 
using ESD from January 2001 to December 2005. The 
follow-up was conducted >5 years after the procedure. The 
patients included 224 men and 95 women, with a mean age of 
71 years (range, 33-92 years). Nineteen patients had multiple 
EGCs with a total of 42 lesions. In the analysis of long-term 
outcomes, 300 patients were enrolled due to the exclusion of 
the 19 patients with multiple EGCs. The overall survival rates 
were compared between the indication and expanded-indi-
cation groups, and between the patients who did or did not 
undergo additional surgery in the out-of-indication group. The 
overall survival rates among different age groups were also 
compared.
Statistical analysis. The statistical significance of the differ-
ences with respect to each complication was determined 
using Fisher's exact test or the χ2 test. Data for the long-term 
outcomes were calculated using the Kaplan-Meier method 
and analyzed by the log-rank test. P<0.05 was considered to 
indicate a statistically significant difference. This study was 
approved by the ethics committee of Nagasaki University 
Hospital.
Results
Early outcomes. Table I categorizes the resected lesions by 
histopathological examination. The indication criteria included 
617 (46.3%) lesions; 507 (38.1%) lesions were included in the 
expanded-indication criteria and 208 (15.6%) lesions were 
included in the out-of-indication criteria. Table II lists the 
early outcomes of the patients. The curative resection rates for 
en bloc resection were 96.6% (596/617) and 91.5% (464/507) 
in the indication and expanded-indication groups, respectively. 
The total perforation rate was 2.9% (39/1,332), and the rate 
for the expanded‑indication group was significantly higher 
than that for the indication group [4.3% (22/507) versus 1.8% 
(11/617), P<0.05; Table III]. Only one case of late-onset perfo-
Table I. All EGC cases categorized by pathology (n=1,332).
Criteria Lesions [n (%)]
Indication [differentiated M UL(‑) ≤20 mm] 617 (46.3%)
Expanded indication 507 (38.1%)
  Differentiated M UL(-) >20 mm 293
  Differentiated M UL(+) ≤30 mm 146
  Differentiated SM1 ≤30 mm   62
  Undifferentiated M UL(‑) ≤20 mm     6
Out of indication 208 (15.6%)
M, mucosal cancer; UL, ulceration; (-), without; (+), with; SM1, 
submucosal invasive cancer.
Table II. Early outcomes.
  Expanded Out of
 Indication indication indication
Outcomes (n=617) (n=507) (n=208)
En bloc 605/617 487/507 199/208
 98.1% 96.1% 95.7%
Curative 596/617 464/507 -
 96.6% 91.5%
Piecemeal or 21/617 43/507 208/208
non-curative 3.4% 8.5% 100%
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ration required surgery. Overall, the ESD-associated bleeding 
rate was 2.0% (26/1,332) and it was significantly higher 
for the out-of-indication group [4.8% (10/208)] compared 
with the indication group [1.1% (7/617)] (P<0.01) or the 
expanded-indication group [1.8% (9/507)] (P<0.05; Table IV). 
The complication rate was similar to those calculated in other 
studies (13‑15). Local recurrence was identified in two patients 
and the lesions in these patients were excised with piecemeal 
resection. 
Long‑term outcomes. Patients (n=319), consisting of 224 men 
and 95 women, with a mean age of 71 years (range, 33-92 years), 
were followed up >5 years after ESD was performed. Of those, 
19 patients (42 lesions) had multiple EGCs; thus, in the analysis 
of long-term outcomes, the other 300 patients were enrolled. 
The median follow-up term of observation was 66 months, 
ranging from 1 to 106 months. Table V presents the categoriza-
tion of the resected lesions that were enrolled in the long-term 
outcome analysis. Of the 49 patients in the out-of-indication 
group, 23 underwent additional surgery and 26 did not due 
to advanced age, concomitant diseases and/or rejection of 
surgery by the patient. Of the 146 patients in the indication 
group, 20 passed away; 18 mortalities were due to diseases 
other than gastric cancer and two were due to unknown 
causes. Of the 105 patients in the expanded-indication group, 
15 patients succumbed to diseases other than gastric cancer. 
Of the 23 patients who underwent additional surgery in the 
out-of-indication group, one mortality occurred, which was 




Expanded indication 1.8% (9/507)
Out of indication 4.8% (10/208)
Total 2.0% (26/1332)
The ESD‑associated later bleeding rate was significantly higher in the 
out-of-indication group compared with the indication group (P<0.01) 
or the expanded-indication group (P<0.05).
Figure 1. Five-year survival rates of the indication and expanded-indication 
groups.
Figure 3. Five-year survival rates of the younger age groups (<60 years old, 
sixties and seventies) and the older age group (>80 years old).
Figure 2. Five-year survival rates of the patients who did or did not undergo 
additional surgery in the out-of-indication group.




Expanded indication 4.3% (22/507)
Out of indication 2.9% (6/208)
Total 2.9% (39/1332)
The perforation rate was significantly higher in the expanded‑indica-
tion group than in the indication group (P<0.05).
Table V. Cases followed up >5 years after ESD, with the 
exception of those with multiple lesions (n=300).
Criteria Patients (n)
Indication (differentiated M UL(‑) ≤20 mm) 146
Expanded indication 105
  Differentiated M UL(-) >20 mm   72
  Differentiated M UL(+) ≤30 mm   21
  Differentiated SM1 ≤30 mm   10
  Undifferentiated M ≤20 mm     2
Out of indication:    49
  Additional surgery (+)   23
  Additional surgery (-)   26
M, mucosal cancer; UL, ulceration; (-), without; (+), with; SM1, 
submucosal invasive cancer.
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not due to gastric cancer. Among the 26 patients who did not 
undergo additional surgery in the out-of-indication group, 
10 mortalities occurred, including one due to gastric cancer. 
The five-year survival rate was not significantly different 
between the indication and expanded-indication groups (Fig. 1). 
However, in the out‑of‑indication group, the five‑year survival 
rate of the patients who did not undergo additional surgery 
(65.0%) was significantly lower than that of the patients who 
did undergo additional surgery (100%) (P=0.0062; Fig. 2). In 
the analysis by age, the five‑year survival rate of the patients 
>80 years old (67.1%) was significantly lower than those of 
the younger age groups (<60 years old, 91.6%; sixties, 93.0%; 
seventies, 84.5%) (P<0.0001; Fig. 3).
Discussion
Gotoda et al (7) suggested that early gastric cancer with no 
risk of lymph node metastasis is definable by using a large 
database, so the indications for endoscopic treatment have 
been expanded in Japan. En bloc resection of ESD provides a 
much higher curative resection rate than piecemeal resection 
via endoscopic mucosal resection (EMR) (11). In addition, 
ESD permits precise histopathological examination for the 
assessment of curability to guide further management and to 
stratify the risk of a patient developing metastases. Successful 
outcomes are therefore enabled following ESD (6,16). In the 
present study, two cases of EGC local recurrence were excised 
via piecemeal resection of ESD. It is important to be able to 
excise via en bloc resection. ESD is an excellent procedure as it 
decreases the incidence of local recurrence following en bloc 
resection more effectively than EMR (17). The development 
of ESD has allowed the indications for endoscopic treatment 
to be extended. In the present study, although the perforation 
rate was higher for the expanded-indication group than for 
the indication group, most of the perforations were controlled 
endoscopically.
Although endoscopic treatment is an accepted therapy for 
EGC in Japan (3-6), there have been few studies concerning 
the long-term outcomes (18,19). The present study has 
demonstrated that the survival rate of patients meeting the 
expanded-indication criteria has been similar to that of patients 
meeting the indication criteria. Therefore, the current expanded 
indications may be appropriate. In the present study, mortali-
ties due to gastric cancer were not observed in the patients in 
the indication and the expanded-indication groups. However, 
13.9% (35/251) of the patients in these two groups succumbed 
to diseases other than gastric cancer. In particular, the survival 
rate of the patients >80 years old was poor; most of the patients 
>80 years of age succumbed to non-cancerous diseases such 
as pulmonary disease, heart disease and cerebral infarction. 
As may be expected, the life expectancies of the older patients 
were shorter than the life expectancies of the younger patients. 
This result may be a natural outcome; however, there are a 
number of studies that suggest ESD is effective even in elderly 
patients (13,18,19). The natural history of EGC has been poorly 
delineated. Therefore, the degree to which EGC improves the 
prognosis of elderly patients, regardless of the presence or 
absence of a therapeutic intervention, has not been fully clari-
fied. In the present study, a number of the elderly patients had 
concomitant diseases, but the mortalities of a number of the 
others were unpredictable. Although it is difficult to decide 
whether elderly patients with EGC should undergo ESD, this 
issue merits careful thought. When the lesions are judged as 
out-of-indication according to histopathological analysis, addi-
tional surgery with lymph node dissection is recommended. In 
the present study, in the out‑of‑indication group, the five‑year 
survival rate of the patients who did not undergo additional 
surgery was significantly lower than that of the patients who 
underwent additional surgery. The reasons for not having addi-
tional surgery included advanced age and comorbid disease, 
and such patients may not require ESD. However, as a number 
of elderly patients may live for a long time, it is difficult to 
decide whether ESD should be performed. This is an issue for 
future study.
In conclusion, the results of the present study demonstrated 
that the early and long-term outcomes of ESD for patients 
meeting the expanded-indication criteria are similar to those 
of patients meeting the indication criteria. When deciding 
whether to perform ESD in elderly patients, it is necessary to 
consider the presence of underlying comorbid diseases.
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